This page describes resources for healthcare professionals to support their patients with CSU.

Patient resources are recommended as a tool for the consistent monitoring of symptoms and routine management of CSU, as:1–3

  • the severity of symptoms can change day to day4
  • no established biomarkers currently exist for CSU5,6
  • key symptoms (such as itch and pain) can only be assessed subjectively

As part of our mission to be as environmentally friendly as possible, we provide our resources in electronic form. These materials should not be printed by healthcare professionals.

Click on the links below to view the patient reported outcomes resources, and if you have any further requests, please contact a Novartis representative.

Symptom control icon

Symptom control


Four questions


Retrospective (4 weeks)

Use at first consultation and every follow-up consultation

Disease severity icon

Disease severity


Two questions

Symptoms scored daily

Prospective (1 week)

Use at every follow-up consultation

Quality of life icon

Quality of life


10 questions

Not specific to CSU

Retrospective (1 week)

Use at first consultation and every 6 months thereafter

*Recommended for evaluating CSU control and monitoring CSU status in routine clinical practice by the EAACI/GA2LEN/EDF/WAO international urticaria guidelines.1

Recommended for monitoring quality of life of patients with urticaria by EAACI/GA2LEN/EDF/WAO, NICE and the BSACI.1,10

BSACI, British Society for Allergy & Clinical Immunology; CSU, chronic spontaneous urticaria; DLQI, Dermatology Life Quality Index; EAACI, European Academy of Allergy and Clinical Immunology; EDF, European Dermatology Forum; GA2LEN, Global Allergy and Asthma European Network; NICE, National Institute for Health and Care Excellence; UAS7, urticaria activity score at seven days; UCT, urticaria control test; WAO, World Allergy Organization.


  1. Zuberbier T, et al. Allergy 2018;73(7):1393–1414.
  2. Maurer M, et al. Allergy 2011;66:317–330.
  3. Moestrup K, et al. Int J Dermatol 2017;56(12):1342–1348.
  4. Flood EM, et al. Patient 2013;6(3):225–231.
  5. Kolkhir P, et al. Clin Exp Allergy 2017;47(1):19–36.
  6. Marzano AV, et al. J Eur Acad Dermatol Venereol 2019;33(5):918–924.
  7. Weller K, et al. J Allergy Clin Immunol 2014;133(5):1365–1372.
  8. Mlynek A, et al. Allergy 2008;63(6):777–780.
  9. Finlay AY, et al. Clin Exp Dermatol 1994;19(3):210–216.
  10. Powell RJ, et al. Clin Exp Allergy 2015;45(3):547–565.
Rate this content: 
No votes yet
UK | October 2021 | 146364

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]